Gemina Laboratories Ltd. (GLABF) Research

Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends to developing unique surface functionalization chemistries specifically designed for the identification of pathogens and various biological markers. A significant ongoing project is the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip intended to determine active COVID-19 infections. The company maintains its corporate headquarters in Vancouver, Canada.

Market snapshot

Symbol
GLABF
Price
$0.05
Day change
0.00%
Market cap
$4.6M
P/E ratio
-1.57x
52-week range
0.0375-0.6179
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AccuStem Sciences Limited (ACMSY)
  • Cell Source, Inc. (CLCS)
  • Hemostemix Inc. (HMTXF)
  • Propanc Biopharma, Inc. (PPCB)
  • PreveCeutical Medical Inc. (PRVCF)
  • Quest PharmaTech Inc. (QPTFF)
  • Sirona Biochem Corp. (SRBCF)
  • Synairgen plc (SYGGF)

Open Gemina Laboratories Ltd. (GLABF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.